The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res
; 178: 104787, 2020 06.
Article
in English
| MEDLINE | ID: covidwho-30819
ABSTRACT
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Virus Replication
/
Ivermectin
/
Drug Approval
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Country/Region as subject:
Oceania
Language:
English
Journal:
Antiviral Res
Year:
2020
Document Type:
Article
Affiliation country:
J.antiviral.2020.104787
Similar
MEDLINE
...
LILACS
LIS